TY  - JOUR
AU  - Lefaucheur, Jean-Pascal
AU  - Andre-Obadia, Nathalie
AU  - Antal, Andrea
AU  - Ayache, Samar S.
AU  - Baeken, Chris
AU  - Benninger, David H.
AU  - Cantello, Roberto M.
AU  - Cincotta, Massimo
AU  - de Carvalho, Mamede
AU  - De Ridder, Dirk
AU  - Devanne, Herve
AU  - Di Lazzaro, Vincenzo
AU  - Filipović, Saša
AU  - Hummel, Friedhelm C.
AU  - Jaaskelainen, Satu K.
AU  - Kimiskidis, Vasilios K.
AU  - Koch, Giacomo
AU  - Langguth, Berthold
AU  - Nyffeler, Thomas
AU  - Oliviero, Antonio
AU  - Padberg, Frank
AU  - Poulet, Emmanuel
AU  - Rossi, Simone
AU  - Rossini, Paolo Maria
AU  - Rothwell, John C.
AU  - Schonfeldt-Lecuona, Carlos
AU  - Siebner, Hartwig R.
AU  - Slotema, Christina W.
AU  - Stagg, Charlotte J.
AU  - Valls-Sole, Josep
AU  - Ziemann, Ulf
AU  - Paulus, Walter
AU  - Garcia-Larrea, Luis
PY  - 2014
UR  - http://rimi.imi.bg.ac.rs/handle/123456789/555
AB  - A group of European experts was commissioned to establish guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) from evidence published up until March 2014, regarding pain, movement disorders, stroke, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, consciousness disorders, tinnitus, depression, anxiety disorders, obsessive-compulsive disorder, schizophrenia, craving/addiction, and conversion. Despite unavoidable inhomogeneities, there is a sufficient body of evidence to accept with level A (definite efficacy) the analgesic effect of high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the pain and the antidepressant effect of HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC). A Level B recommendation (probable efficacy) is proposed for the antidepressant effect of low-frequency (LF) rTMS of the right DLPFC, HF-rTMS of the left DLPFC for the negative symptoms of schizophrenia, and LF-rTMS of contralesional M1 in chronic motor stroke. The effects of rTMS in a number of indications reach level C (possible efficacy), including LF-rTMS of the left temporoparietal cortex in tinnitus and auditory hallucinations. It remains to determine how to optimize rTMS protocols and techniques to give them relevance in routine clinical practice. In addition, professionals carrying out rTMS protocols should undergo rigorous training to ensure the quality of the technical realization, guarantee the proper care of patients, and maximize the chances of success. Under these conditions, the therapeutic use of rTMS should be able to develop in the coming years.
PB  - Elsevier Ireland Ltd, Clare
T2  - Clinical Neurophysiology
T1  - Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)
EP  - 2206
IS  - 11
SP  - 2150
VL  - 125
DO  - 10.1016/j.clinph.2014.05.021
ER  - 

@article{
author = "Lefaucheur, Jean-Pascal and Andre-Obadia, Nathalie and Antal, Andrea and Ayache, Samar S. and Baeken, Chris and Benninger, David H. and Cantello, Roberto M. and Cincotta, Massimo and de Carvalho, Mamede and De Ridder, Dirk and Devanne, Herve and Di Lazzaro, Vincenzo and Filipović, Saša and Hummel, Friedhelm C. and Jaaskelainen, Satu K. and Kimiskidis, Vasilios K. and Koch, Giacomo and Langguth, Berthold and Nyffeler, Thomas and Oliviero, Antonio and Padberg, Frank and Poulet, Emmanuel and Rossi, Simone and Rossini, Paolo Maria and Rothwell, John C. and Schonfeldt-Lecuona, Carlos and Siebner, Hartwig R. and Slotema, Christina W. and Stagg, Charlotte J. and Valls-Sole, Josep and Ziemann, Ulf and Paulus, Walter and Garcia-Larrea, Luis",
year = "2014",
abstract = "A group of European experts was commissioned to establish guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS) from evidence published up until March 2014, regarding pain, movement disorders, stroke, amyotrophic lateral sclerosis, multiple sclerosis, epilepsy, consciousness disorders, tinnitus, depression, anxiety disorders, obsessive-compulsive disorder, schizophrenia, craving/addiction, and conversion. Despite unavoidable inhomogeneities, there is a sufficient body of evidence to accept with level A (definite efficacy) the analgesic effect of high-frequency (HF) rTMS of the primary motor cortex (M1) contralateral to the pain and the antidepressant effect of HF-rTMS of the left dorsolateral prefrontal cortex (DLPFC). A Level B recommendation (probable efficacy) is proposed for the antidepressant effect of low-frequency (LF) rTMS of the right DLPFC, HF-rTMS of the left DLPFC for the negative symptoms of schizophrenia, and LF-rTMS of contralesional M1 in chronic motor stroke. The effects of rTMS in a number of indications reach level C (possible efficacy), including LF-rTMS of the left temporoparietal cortex in tinnitus and auditory hallucinations. It remains to determine how to optimize rTMS protocols and techniques to give them relevance in routine clinical practice. In addition, professionals carrying out rTMS protocols should undergo rigorous training to ensure the quality of the technical realization, guarantee the proper care of patients, and maximize the chances of success. Under these conditions, the therapeutic use of rTMS should be able to develop in the coming years.",
publisher = "Elsevier Ireland Ltd, Clare",
journal = "Clinical Neurophysiology",
title = "Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)",
pages = "2206-2150",
number = "11",
volume = "125",
doi = "10.1016/j.clinph.2014.05.021"
}

Lefaucheur, J., Andre-Obadia, N., Antal, A., Ayache, S. S., Baeken, C., Benninger, D. H., Cantello, R. M., Cincotta, M., de Carvalho, M., De Ridder, D., Devanne, H., Di Lazzaro, V., Filipović, S., Hummel, F. C., Jaaskelainen, S. K., Kimiskidis, V. K., Koch, G., Langguth, B., Nyffeler, T., Oliviero, A., Padberg, F., Poulet, E., Rossi, S., Rossini, P. M., Rothwell, J. C., Schonfeldt-Lecuona, C., Siebner, H. R., Slotema, C. W., Stagg, C. J., Valls-Sole, J., Ziemann, U., Paulus, W.,& Garcia-Larrea, L.. (2014). Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). in Clinical Neurophysiology
Elsevier Ireland Ltd, Clare., 125(11), 2150-2206.
https://doi.org/10.1016/j.clinph.2014.05.021

Lefaucheur J, Andre-Obadia N, Antal A, Ayache SS, Baeken C, Benninger DH, Cantello RM, Cincotta M, de Carvalho M, De Ridder D, Devanne H, Di Lazzaro V, Filipović S, Hummel FC, Jaaskelainen SK, Kimiskidis VK, Koch G, Langguth B, Nyffeler T, Oliviero A, Padberg F, Poulet E, Rossi S, Rossini PM, Rothwell JC, Schonfeldt-Lecuona C, Siebner HR, Slotema CW, Stagg CJ, Valls-Sole J, Ziemann U, Paulus W, Garcia-Larrea L. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). in Clinical Neurophysiology. 2014;125(11):2150-2206.
doi:10.1016/j.clinph.2014.05.021 .

Lefaucheur, Jean-Pascal, Andre-Obadia, Nathalie, Antal, Andrea, Ayache, Samar S., Baeken, Chris, Benninger, David H., Cantello, Roberto M., Cincotta, Massimo, de Carvalho, Mamede, De Ridder, Dirk, Devanne, Herve, Di Lazzaro, Vincenzo, Filipović, Saša, Hummel, Friedhelm C., Jaaskelainen, Satu K., Kimiskidis, Vasilios K., Koch, Giacomo, Langguth, Berthold, Nyffeler, Thomas, Oliviero, Antonio, Padberg, Frank, Poulet, Emmanuel, Rossi, Simone, Rossini, Paolo Maria, Rothwell, John C., Schonfeldt-Lecuona, Carlos, Siebner, Hartwig R., Slotema, Christina W., Stagg, Charlotte J., Valls-Sole, Josep, Ziemann, Ulf, Paulus, Walter, Garcia-Larrea, Luis, "Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS)" in Clinical Neurophysiology, 125, no. 11 (2014):2150-2206,
https://doi.org/10.1016/j.clinph.2014.05.021 . .